OBJECTIVE: Several interventions promote axonal growth and functional recovery when initiated shortly after central nervous system injury, including blockade of myelin-derived inhibitors with soluble Nogo receptor (NgR1, RTN4R) decoy protein. We examined the efficacy of this intervention in the much more prevalent and refractory condition of chronic spinal cord injury. METHODS: We eliminated the NgR1 pathway genetically in mice by conditional gene targeting starting 8 weeks after spinal hemisection injury and monitored locomotion in the open field and by video kinematics over the ensuing 4 months. In a separate pharmacological experiment, intrathecal NgR1 decoy protein administration was initiated 3 months after spinal cord contusion injury. Locomotion and raphespinal axon growth were assessed during 3 months of treatment between 4 and 6 months after contusion injury. RESULTS: Conditional deletion of NgR1 in the chronic state results in gradual improvement of motor function accompanied by increased density of raphespinal axons in the caudal spinal cord. In chronic rat spinal contusion, NgR1 decoy treatment from 4 to 6 months after injury results in 29% (10 of 35) of rats recovering weight-bearing status compared to 0% (0 of 29) of control rats (p < 0.05). Open field Basso, Beattie, and Bresnahan locomotor scores showed a significant improvement in the NgR-treated group relative to the control group (p < 0.005, repeated measures analysis of variance). An increase in raphespinal axon density caudal to the injury is detected in NgR1 decoy-treated animals by immunohistology and by positron emission tomography using a serotonin reuptake ligand. INTERPRETATION: Antagonizing myelin-derived inhibitors signaling with NgR1 decoy augments recovery from chronic spinal cord injury.
OBJECTIVE: Several interventions promote axonal growth and functional recovery when initiated shortly after central nervous system injury, including blockade of myelin-derived inhibitors with soluble Nogo receptor (NgR1, RTN4R) decoy protein. We examined the efficacy of this intervention in the much more prevalent and refractory condition of chronic spinal cord injury. METHODS: We eliminated the NgR1 pathway genetically in mice by conditional gene targeting starting 8 weeks after spinal hemisection injury and monitored locomotion in the open field and by video kinematics over the ensuing 4 months. In a separate pharmacological experiment, intrathecal NgR1 decoy protein administration was initiated 3 months after spinal cord contusion injury. Locomotion and raphespinal axon growth were assessed during 3 months of treatment between 4 and 6 months after contusion injury. RESULTS: Conditional deletion of NgR1 in the chronic state results in gradual improvement of motor function accompanied by increased density of raphespinal axons in the caudal spinal cord. In chronic rat spinal contusion, NgR1 decoy treatment from 4 to 6 months after injury results in 29% (10 of 35) of rats recovering weight-bearing status compared to 0% (0 of 29) of control rats (p < 0.05). Open field Basso, Beattie, and Bresnahan locomotor scores showed a significant improvement in the NgR-treated group relative to the control group (p < 0.005, repeated measures analysis of variance). An increase in raphespinal axon density caudal to the injury is detected in NgR1 decoy-treated animals by immunohistology and by positron emission tomography using a serotonin reuptake ligand. INTERPRETATION: Antagonizing myelin-derived inhibitors signaling with NgR1 decoy augments recovery from chronic spinal cord injury.
Authors: J D Steeves; D Lammertse; A Curt; J W Fawcett; M H Tuszynski; J F Ditunno; P H Ellaway; M G Fehlings; J D Guest; N Kleitman; P F Bartlett; A R Blight; V Dietz; B H Dobkin; R Grossman; D Short; M Nakamura; W P Coleman; M Gaviria; A Privat Journal: Spinal Cord Date: 2006-12-19 Impact factor: 2.772
Authors: D Michele Basso; Lesley C Fisher; Aileen J Anderson; Lyn B Jakeman; Dana M McTigue; Phillip G Popovich Journal: J Neurotrauma Date: 2006-05 Impact factor: 5.269
Authors: James H Park; David A Gimbel; Tadzia GrandPre; Jung-Kil Lee; Ji-Eun Kim; Weiwei Li; Daniel H S Lee; Stephen M Strittmatter Journal: J Neurosci Date: 2006-02-01 Impact factor: 6.167
Authors: William B J Cafferty; Shih-Hung Yang; Philip J Duffy; Shuxin Li; Stephen M Strittmatter Journal: J Neurosci Date: 2007-02-28 Impact factor: 6.167
Authors: J W Fawcett; A Curt; J D Steeves; W P Coleman; M H Tuszynski; D Lammertse; P F Bartlett; A R Blight; V Dietz; J Ditunno; B H Dobkin; L A Havton; P H Ellaway; M G Fehlings; A Privat; R Grossman; J D Guest; N Kleitman; M Nakamura; M Gaviria; D Short Journal: Spinal Cord Date: 2006-12-19 Impact factor: 2.772
Authors: Philip Duffy; Xingxing Wang; Chad S Siegel; Chad S Seigel; Nathan Tu; Mark Henkemeyer; William B J Cafferty; Stephen M Strittmatter Journal: Proc Natl Acad Sci U S A Date: 2012-03-12 Impact factor: 11.205
Authors: Xingxing Wang; Omar Hasan; Alexander Arzeno; Larry I Benowitz; William B J Cafferty; Stephen M Strittmatter Journal: Exp Neurol Date: 2012-06-21 Impact factor: 5.330
Authors: Céleste-Élise Stephany; Xiaokuang Ma; Hilary M Dorton; Jie Wu; Alexander M Solomon; Michael G Frantz; Shenfeng Qiu; Aaron W McGee Journal: Curr Biol Date: 2018-06-07 Impact factor: 10.834
Authors: Jennifer L Konopka-Anstadt; Bernardo A Mainou; Danica M Sutherland; Yuichi Sekine; Stephen M Strittmatter; Terence S Dermody Journal: Cell Host Microbe Date: 2014-06-11 Impact factor: 21.023
Authors: Brian J Kelley; Noam Y Harel; Chang-Yeon Kim; Xenophon Papademetris; Daniel Coman; Xingxing Wang; Omar Hasan; Adam Kaufman; Ronen Globinsky; Lawrence H Staib; William B J Cafferty; Fahmeed Hyder; Stephen M Strittmatter Journal: J Neurotrauma Date: 2014-07-08 Impact factor: 5.269
Authors: Xingxing Wang; Kazim Yigitkanli; Chang-Yeon Kim; Tomoko Sekine-Komo; Dana Wirak; Eric Frieden; Ajay Bhargava; George Maynard; William B J Cafferty; Stephen M Strittmatter Journal: J Neurotrauma Date: 2014-10-16 Impact factor: 5.269